Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Multiple Myeloma 15Melanoma 14Carcinoma, Non-Small-Cell Lung 13Recurrence 12Neoplasms 12Leukemia, Myeloid, Acute 9Glioblastoma 8Prostatic Neoplasms 6Lung Neoplasms 6Breast Neoplasms 6Lymphoma 5Glioma 5Carcinoma, Renal Cell 5Sarcoma 4Pancreatic Neoplasms 4Lymphoma, Non-Hodgkin 4Gastrointestinal Stromal Tumors 4Colorectal Neoplasms 4Triple Negative Breast Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Carcinoma 3Solid Tumors 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Neoplasms by Site 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large-Cell, Anaplastic 2Liver Neoplasms 2Leukemia 2

Interventions

lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × INDUSTRY × Non Small Cell Lung Cancer ALK Positive or ROS1 Positive × Clear all
NCT03178071 2019-11-04

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

Pfizer

No longer available
Thoracic

Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡